Literature DB >> 12174370

Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance.

Xiao-Yong Fu1, Hong-Yang Wang, Lu Tan, Shu-Qin Liu, Hui-Fang Cao, Meng-Chao Wu.   

Abstract

AIM: To investigate the expression of p28/gankyrin gene and its role in the carcinogenetic process of human hepatocellular carcinoma (HCC).
METHODS: 64 specimens of HCC and para-carcinoma tissues, 22 specimens of non-tumor liver tissues (7 normal, 15 cirrhosis), 10 specimens of normal human tissues and 5 hepatoma cell lines were studied for the expression of p28/gankyrin by Northern blot. The expression of p28/gankyrin protein was detected immunohistochemically by using the specific polyclonal antibody.
RESULTS: Northern blot analysis indicated that the expression of p28/gankyrin mRNA was intensively distributed in brain and heart, weakly in lung, spleen and muscle, undetectable in digestive system including liver, pancreas, stomach, small and large intestines. p28/gankyrin mRNA was absent in normal liver, weakly detected in liver cirrhosis and in 18 of 64 para-carcinoma liver tissues. In contrast, the expression of p28/gankyrin mRNA was intensively detected in all 5 hepatoma cell lines tested, markedly increased in 57 of 64 and moderately increased in 5 of 64 HCC samples. In comparison with liver cirrhosis and para-carcinoma liver tissues, the average expression of p28/gankyrin mRNA in HCC was increased 3.6- (2.901+/-0.507 vs 0.805+/-0.252, P<0.05) and 5.2-fold (2.901+/-0.507 vs 0.557+/-0.203, P<0.01), respectively. In addition, p28/gankyrin mRNA expression level was higher in HCC with portal vein tumor thrombus and microscopic hepatic vein involvement (P=0.021 and P=0.047, respectively). The overexpression of p28/gankyrin protein in HCC was targeted in hepatic tumor cells, not in bile duct cells and other interstitial cells.
CONCLUSION: Overexpression of p28/gankyrin in HCC plays an important role and contributes to the metastasis potential in the process of carcinogenesis. p28/gankyrin may become a specific biological tissue marker for the pathological diagnosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174370      PMCID: PMC4656312          DOI: 10.3748/wjg.v8.i4.638

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

Review 2.  The ubiquitin-proteasome pathway: on protein death and cell life.

Authors:  A Ciechanover
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

3.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas.

Authors:  H Higashitsuji; K Itoh; T Nagao; S Dawson; K Nonoguchi; T Kido; R J Mayer; S Arii; J Fujita
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.

Authors:  K Yuki; S Hirohashi; M Sakamoto; T Kanai; Y Shimosato
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

5.  Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel.

Authors:  A Toyosaka; E Okamoto; M Mitsunobu; T Oriyama; N Nakao; K Miura
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

Review 6.  Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach.

Authors:  A Sylla; M S Diallo; J Castegnaro; C P Wild
Journal:  Mutat Res       Date:  1999-07-16       Impact factor: 2.433

7.  High frequency of p16INK4A gene alterations in hepatocellular carcinoma.

Authors:  C T Liew; H M Li; K W Lo; C K Leow; J Y Chan; L Y Hin; W Y Lau; P B Lai; B K Lim; J Huang; W T Leung; S Wu; J C Lee
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

8.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

9.  Incorporation and metabolic conversion of saturated and unsaturated fatty acids in SK-Hep1 human hepatoma cells in culture.

Authors:  C A Marra; M J de Alaniz
Journal:  Mol Cell Biochem       Date:  1992-11-18       Impact factor: 3.396

10.  Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers.

Authors:  M W Yu; Y H Chiu; S Y Yang; R M Santella; H D Chern; Y F Liaw; C J Chen
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  30 in total

1.  Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.

Authors:  Ru-Lin Cai; Wei Meng; Hong-Yan Lu; Wen-Yao Lin; Feng Jiang; Fu-Min Shen
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  Localization of TRAIL/TRAILR in fetal pancreas.

Authors:  Li-Hua Chen; Xue-Song Liu; Wen-Yong Wang; Wei-Ning Han; Bo-Rong Pan; Bo-Quan Jin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 3.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

Review 4.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

5.  MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.

Authors:  Yu Wang; Han Chong Toh; Pierce Chow; Alexander Y F Chung; David J Meyers; Philip A Cole; London L P J Ooi; Caroline G L Lee
Journal:  FASEB J       Date:  2012-03-29       Impact factor: 5.191

6.  Minority stress and leukocyte gene expression in sexual minority men living with treated HIV infection.

Authors:  Annesa Flentje; Kord M Kober; Adam W Carrico; Torsten B Neilands; Elena Flowers; Nicholas C Heck; Bradley E Aouizerat
Journal:  Brain Behav Immun       Date:  2018-03-13       Impact factor: 7.217

Review 7.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 8.  The impact of hypoxia in hepatocellular carcinoma metastasis.

Authors:  Carmen Chak-Lui Wong; Alan Ka-Lun Kai; Irene Oi-Lin Ng
Journal:  Front Med       Date:  2013-11-14       Impact factor: 4.592

9.  Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.

Authors:  Anjali Mahajan; Yi Guo; Chunhua Yuan; Christopher M Weghorst; Ming-Daw Tsai; Junan Li
Journal:  J Mol Biol       Date:  2007-08-22       Impact factor: 5.469

10.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.